210 related articles for article (PubMed ID: 15334308)
1. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
Miyachi H
IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
[TBL] [Abstract][Full Text] [Related]
2. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
[TBL] [Abstract][Full Text] [Related]
3. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
[TBL] [Abstract][Full Text] [Related]
4. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
[TBL] [Abstract][Full Text] [Related]
6. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Sierra ML; Beneton V; Boullay AB; Boyer T; Brewster AG; Donche F; Forest MC; Fouchet MH; Gellibert FJ; Grillot DA; Lambert MH; Laroze A; Le Grumelec C; Linget JM; Montana VG; Nguyen VL; Nicodème E; Patel V; Penfornis A; Pineau O; Pohin D; Potvain F; Poulain G; Ruault CB; Saunders M; Toum J; Xu HE; Xu RX; Pianetti PM
J Med Chem; 2007 Feb; 50(4):685-95. PubMed ID: 17243659
[TBL] [Abstract][Full Text] [Related]
7. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
8. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
9. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor.
Wurch T; Junquero D; Delhon A; Pauwels J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):133-40. PubMed ID: 11819031
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Asaki T; Aoki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
Bioorg Med Chem; 2008 Jan; 16(2):981-94. PubMed ID: 17964792
[TBL] [Abstract][Full Text] [Related]
15. Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes.
Barbier O; Fontaine C; Fruchart JC; Staels B
Trends Endocrinol Metab; 2004 Sep; 15(7):324-30. PubMed ID: 15350604
[TBL] [Abstract][Full Text] [Related]
16. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes.
Mazzucotelli A; Viguerie N; Tiraby C; Annicotte JS; Mairal A; Klimcakova E; Lepin E; Delmar P; Dejean S; Tavernier G; Lefort C; Hidalgo J; Pineau T; Fajas L; Clément K; Langin D
Diabetes; 2007 Oct; 56(10):2467-75. PubMed ID: 17646210
[TBL] [Abstract][Full Text] [Related]
17. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
[TBL] [Abstract][Full Text] [Related]
18. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Grau R; Punzón C; Fresno M; Iñiguez MA
Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
[TBL] [Abstract][Full Text] [Related]
20. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
